QuidelOrtho Completes Acquisition of LEX Diagnostics
Summary
QuidelOrtho Corporation has announced the completion of its acquisition of LEX Diagnostics. This strategic transaction represents a new development for the company, following recent negative news regarding its preliminary first-quarter 2026 revenue guidance, which caused a significant decline in its stock price. The acquisition is expected to expand QuidelOrtho's product portfolio and strategic capabilities. Traders will now monitor for further details on the financial terms and the anticipated impact of LEX Diagnostics on QuidelOrtho's future performance, especially as the company addresses its recent revenue challenges.
At the time of this announcement, QDEL was trading at $12.41 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $865.3M. The 52-week trading range was $11.61 to $38.99. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.